ophthalmology

News

Novartis drops geographic atrophy gene therapy

Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy (GA) two years after acquiring its UK-based developer

News

Outlook slumps as FDA rejects eye disease drug

Shares in Outlook Therapeutics cratered today after the FDA rejected the company's marketing application for its lead drug ONS-5010, a therapy for age-related macular dege

News

After earlier rejection, high-dose Eylea clears FDA

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the

R&D

Improving treatment for high-risk cataract surgery

Cataracts rank among the most prevalent age-related ailments.

News

Astellas' Iveric takeover rewarded with FDA nod for GA drug

The FDA has approved a new drug for sight-robbing disease geographic atrophy from Astellas, just a few weeks after the company

News

Tenpoint raises $70m for vision loss therapies

UK-headquartered start-up Tenpoint Therapeutics has reeled in a commendable $70 million in first-round financing that will be used to develop its cell-based therapies for

Novartis drops geographic atrophy gene therapy

Outlook slumps as FDA rejects eye disease drug

After earlier rejection, high-dose Eylea clears FDA

Improving treatment for high-risk cataract surgery

Astellas' Iveric takeover rewarded with FDA nod for GA drug

Tenpoint raises $70m for vision loss therapies

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

ophthalmology

Editor's Picks